FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2499961566> ?p ?o ?g. }

• W2499961566 abstract "Letter to the Editor In his review article, Dr. Mahesh [1] discussed the pathophysiology and management of hyponatremia in patients with cirrhosis and ascites. He noted hyponatremia as a problematic complication in cirrhotic patients. Recent studies strongly support this contention. Among patients with liver disease, hyponatremia is recognized as a predictive factor of poor quality-of-life and early death, independent of liver function tests, Child-Pugh criteria and Model for End-Stage Liver Disease scores [2, 3]. Dr. Mahesh presented a clear and stepwise approach in managing hyponatremia in this challenging patient population. His approach starts with modest water restriction, followed by withholding of loop diuretics and strict fluid restriction once plasma sodium drops below 126 meq/L [1]. He also briefly mentioned other treatment strategies. In the last paragraph, he stated: “vasopressin receptor analogues, demeclocycline etc have been tried, but no definite benefit”. I think the above statement is a typographical error. I believe that Dr. Mahesh was pertaining to vasopressin receptor antagonists and not to vasopressin receptor analogues, as published. Vasopressin receptor analogues have never been used to treat hyponatremia. On the other hand, vasopressin receptor antagonists, also called vaptans, are beginning to be recognized as effective and safe pharmacologic agents in euvolemic and hypervolemic hyponatremia such as in the case of cirrhosis with ascites [4]. Vaptans are non-peptide, argininevasopressin-receptor antagonists. They are orally and intravenously active. They work by antagonizing the effects of Arginine Vasopressin or Anti-Diuretic Hormone. This improves solute-free water excretion in the renal tubules [5]. Gines et al. [6] have shown improved serum sodium concentration in patients with cirrhosis after the first day of vaptan therapy. Correction of hyponatremia is observed in 27% to 54% of patients with cirrhosis [7]. Understandably, the correction of hyponatremia due to secondary causes such as cirrhosis and congestive heart failure is particularly difficult. The therapeutic approach must always address the underlying condition. In 2005, the U.S. Food and Drug Administration approved the use of conivaptan (Vaprisol®). Other vaptans in various phases of clinical or marketing development include: mozavaptan, lixivaptan, satavaptan and tolvaptan. There is still more to be learned regarding the use of vaptans in cirrhotic patients with hyponatremia. There has been no extensive investigation comparing clinical outcomes and effectiveness of vaptans against the usual interventions such as water restriction and withholding of loop diuretics. To end, the paper of Dr.Mahesh raises an important point regarding the prudence of slow and careful serum sodium correction. Chronic asymptomatic hyponatremia should be corrected at a slow rate of < 12 mmol/L/day. If ever vaptans would be employed in the treatment, their infusion should be stopped once serum sodium reaches 134 mmol/L, to avoid the risk of osmotic demyelination resulting to catastrophic central pontine myelinolysis [8]." @default.
• W2499961566 created "2016-08-23" @default.
• W2499961566 date "2009-01-01" @default.
• W2499961566 modified "2023-09-26" @default.
• W2499961566 title "Treatment of Hyponatremia in Cirrhosis" @default.
• W2499961566 cites W1967812386 @default.
• W2499961566 cites W1979393114 @default.
• W2499961566 cites W2012308949 @default.
• W2499961566 cites W2055162608 @default.
• W2499961566 cites W2104748479 @default.
• W2499961566 cites W2475432591 @default.
• W2499961566 doi "https://doi.org/10.5580/1df7" @default.
• W2499961566 hasPublicationYear "2009" @default.
• W2499961566 type Work @default.
• W2499961566 sameAs 2499961566 @default.
• W2499961566 citedByCount "0" @default.
• W2499961566 crossrefType "journal-article" @default.
• W2499961566 hasConcept C126322002 @default.
• W2499961566 hasConcept C2776703092 @default.
• W2499961566 hasConcept C2777214474 @default.
• W2499961566 hasConcept C71924100 @default.
• W2499961566 hasConceptScore W2499961566C126322002 @default.
• W2499961566 hasConceptScore W2499961566C2776703092 @default.
• W2499961566 hasConceptScore W2499961566C2777214474 @default.
• W2499961566 hasConceptScore W2499961566C71924100 @default.
• W2499961566 hasIssue "2" @default.
• W2499961566 hasLocation W24999615661 @default.
• W2499961566 hasOpenAccess W2499961566 @default.
• W2499961566 hasPrimaryLocation W24999615661 @default.
• W2499961566 hasRelatedWork W2183315091 @default.
• W2499961566 hasRelatedWork W2361433847 @default.
• W2499961566 hasRelatedWork W2372270627 @default.
• W2499961566 hasRelatedWork W2385697996 @default.
• W2499961566 hasRelatedWork W2386960718 @default.
• W2499961566 hasRelatedWork W2389726796 @default.
• W2499961566 hasRelatedWork W2413435160 @default.
• W2499961566 hasRelatedWork W2903067590 @default.
• W2499961566 hasRelatedWork W4231129228 @default.
• W2499961566 hasRelatedWork W2531078887 @default.
• W2499961566 hasVolume "7" @default.
• W2499961566 isParatext "false" @default.
• W2499961566 isRetracted "false" @default.
• W2499961566 magId "2499961566" @default.
• W2499961566 workType "article" @default.